The impact of novel therapeutic agents before and after frontline autologous stem cell transplantation in patients with multiple myeloma

BACKGROUND: Novel agents (NAs) such as thalidomide and bortezomib have been administered in combination with autologous stem-cell transplantation (ASCT) to effectively treat multiple myeloma (MM). However, whether NAs perform better as induction treatments prior to transplantation, or as post-transp...

Descripción completa

Detalles Bibliográficos
Autores principales: Min, Chang-Ki, Lee, Sung-Eun, Yahng, Seung-Ah, Cho, Byung-Sik, Eom, Ki-Seong, Kim, Yoo-Jin, Kim, Hee-Je, Lee, Seok, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong-Wook, Min, Woo-Sung, Park, Chong-Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2013
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786280/
https://www.ncbi.nlm.nih.gov/pubmed/24086940
http://dx.doi.org/10.5045/br.2013.48.3.198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3786280/
https://www.ncbi.nlm.nih.gov/pubmed/24086940
http://dx.doi.org/10.5045/br.2013.48.3.198

Ejemplares similares